Source: Theratechnologies Inc.
  • Theratechnologies (TH) will present at the H.C. Wainwright 5th Annual Nash Investor Conference
  • A live webcast of Dr. Marsolais’ presentation will be available through the ‘Events’ section of its investor relations website
  • Prior to this, the last news Teratech came out with was on September 29 of this year
  • It will report Q3 financial results on Wednesday, October 13, 2021
  • Theratechnologies is a biopharmaceutical company
  • Theratechnologies (TH) is down 1.78 per cent, trading at C$4.42 at 12:39 pm ET

Theratechnologies’ (TH) Senior Vice President and Chief Medical Officer Dr. Marsolais will present at the H.C. Wainwright NASH Investor Conference.

A live webcast of Dr. Marsolais’ presentation will be available through the ‘Events’ section of its investor relations website and will be archived for 90 days.

In other news, Teratech will report financial results for its third quarter of fiscal 2021 on October 13th.

A conference call will be held on October 13 at 8:30 am ET to discuss the results and recent business updates.

The call will be hosted by Paul Lévesque, President and Chief Executive Officer. Mr. Lévesque and other members of the management team will be available to answer questions from participants following prepared remarks.

Theratechnologies is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 

Theratechnologies (TH) is down 1.78 per cent, trading at C$4.42 at 12:39 pm ET.

More From The Market Online

Buzz on the Bullboards: Looking for volatility-proof stocks?

Investors saw developments in Canadian and U.S. stock markets, with attention on decisions made by central banks and moves in key sectors.
Scientific labratory

How a small-cap tech stock is broadening MRI technology 

Nanalysis Scientific (TSXV:NSCI) develops and makes compact MRI and nuclear magnetic resonance devices for clinical, lab and industrial use.

PharmAla Biotech launches educational portal for MDMA

PharmAla Biotech (CSE:MDMA) launches its Prescribers Portal for medical practitioners to learn more about MDMA.

Cancer-fighting pharma stock eyes 2027 regulatory approval

Theralase Technologies (TSXV:TLT), a cancer-fighting pharma stock, expands its team with two clinical research associates.